News | November 14, 2024
AstraZeneca invests US$ 3.5 billion in R&D and manufacturing in US
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Subscribe To Our Newsletter & Stay Updated
